APVO
Income statement / Annual
Last year (2023), Aptevo Therapeutics Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2023, Aptevo Therapeutics Inc.'s net income was -$17.41 M.
See Aptevo Therapeutics Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
$3.11 M
|
$12.29 M
|
$4.31 M
|
$32.42 M
|
$23.07 M
|
$14.66 M
|
$36.43 M
|
$33.60 M
|
$45.63 M
|
| Cost of Revenue |
$567,000.00 |
$901,000.00 |
$18.99 M |
$17.85 M |
$19.93 M |
$11.21 M |
$5.01 M |
$24.18 M |
$16.93 M |
$16.25 M |
| Gross Profit |
-$567,000.00 |
$2.21 M |
-$6.70 M |
-$13.54 M |
$12.50 M |
$11.85 M |
$9.65 M |
$12.25 M |
$16.67 M |
$29.38 M |
| Gross Profit Ratio |
0 |
0.71 |
-0.55 |
-3.14 |
0.39 |
0.51 |
0.66 |
0.34 |
0.5 |
0.64 |
| Research and Development
Expenses |
$16.54 M
|
$17.88 M
|
$18.99 M
|
$17.85 M
|
$24.76 M
|
$35.39 M
|
$29.02 M
|
$29.52 M
|
$34.73 M
|
$46.59 M
|
| General & Administrative
Expenses |
$11.77 M
|
$13.87 M
|
$14.70 M
|
$13.95 M
|
$16.20 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$11.77 M
|
$13.87 M
|
$14.70 M
|
$13.95 M
|
$16.20 M
|
$28.13 M
|
$34.58 M
|
$38.67 M
|
$43.04 M
|
$34.28 M
|
| Other Expenses |
$0.00 |
-$1.53 M |
-$8.01 M |
-$1.33 M |
-$2.10 M |
-$2.02 M |
$34.58 M |
$38.67 M |
$43.04 M |
$34.28 M |
| Operating Expenses |
$28.88 M |
$31.76 M |
$33.69 M |
$31.80 M |
$40.96 M |
$63.52 M |
$63.60 M |
$68.18 M |
$77.77 M |
$80.87 M |
| Cost And Expenses |
$28.88 M |
$31.76 M |
$33.69 M |
$31.80 M |
$40.96 M |
$74.73 M |
$68.61 M |
$92.37 M |
$94.70 M |
$97.12 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$567,000.00
|
$901,000.00
|
$1.14 M
|
$1.41 M
|
$2.24 M
|
$2.39 M
|
$2.30 M
|
$1.90 M
|
$2.91 M
|
$2.02 M
|
| EBITDA |
-$28.31 M
|
-$27.74 M
|
-$20.26 M
|
-$26.09 M
|
-$39.53 M
|
-$49.28 M
|
-$50.82 M
|
-$64.40 M
|
-$58.19 M
|
-$49.47 M
|
| EBITDA Ratio |
0 |
-20.85 |
-1.74 |
-5.89 |
-1.19 |
-2.14 |
-3.33 |
0.53 |
-1.72 |
-1.08 |
| Operating Income Ratio
|
0
|
-9.2
|
-1.74
|
-6.38
|
-1.26
|
-2.24
|
-3.68
|
-3.48
|
-1.82
|
-1.13
|
| Total Other
Income/Expenses Net |
$10.23 M
|
$35.66 M
|
-$8.01 M
|
-$3.43 M
|
-$2.10 M
|
-$2.02 M
|
-$1.94 M
|
-$12.64 M
|
-$237,000.00
|
-$222,000.00
|
| Income Before Tax |
-$18.65 M |
$7.01 M |
-$29.41 M |
-$30.92 M |
-$43.06 M |
-$53.69 M |
-$55.89 M |
-$127.76 M |
-$61.34 M |
-$51.71 M |
| Income Before Tax Ratio
|
0
|
2.25
|
-2.39
|
-7.18
|
-1.33
|
-2.33
|
-3.81
|
-3.51
|
-1.83
|
-1.13
|
| Income Tax Expense |
$0.00 |
-$35.66 M |
-$2.10 M |
-$12.48 M |
-$2.62 M |
-$2.02 M |
-$23.30 M |
-$15.34 M |
-$2.02 M |
-$599,000.00 |
| Net Income |
-$17.41 M |
$42.67 M |
-$27.31 M |
-$18.45 M |
-$40.45 M |
-$53.69 M |
$6.97 M |
-$112.42 M |
-$59.32 M |
-$51.12 M |
| Net Income Ratio |
0 |
13.7 |
-2.22 |
-4.28 |
-1.25 |
-2.33 |
0.48 |
-3.09 |
-1.77 |
-1.12 |
| EPS |
-72.01 |
366.71 |
-256.35 |
-239.38 |
-610.11 |
-1469.88 |
-941.01 |
-3421.45 |
-1806.19 |
-1556.44 |
| EPS Diluted |
-67.07 |
367.92 |
-256.35 |
-239.38 |
-610.11 |
-1469.88 |
-941.01 |
-3421.45 |
-1806.19 |
-1556.44 |
| Weighted Average Shares
Out |
$259,000.00
|
$116,357.00
|
$106,544.00
|
$77,066.00
|
$66,296.00
|
$36,526.00
|
$34,635.00
|
$32,856.00
|
$32,841.00
|
$32,841.00
|
| Weighted Average Shares
Out Diluted |
$278,061.00
|
$115,975.00
|
$106,544.00
|
$77,066.00
|
$66,296.00
|
$36,526.00
|
$34,635.00
|
$32,856.00
|
$32,841.00
|
$32,841.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
